Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies

Neurobiology of Aging

Volumn 35, Issue 6, 2014, Pages 1483-1490

  Graff Radford, Jonathan ^a   Boeve, Bradley F ^a   Murray, Melissa E ^b   Ferman, Tanis J ^b   Tosakulwong, Nirubol ^c   Lesnick, Timothy G ^c   Maroney Smith, Mandie ^a   Senjem, Matthew L ^a   Gunter, Jeffrey ^a   Smith, Glenn E ^a   Knopman, David S ^a   Jack, Clifford R ^a   Dickson, Dennis W ^b   Petersen, Ronald C ^a   Kantarci, Kejal ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c NONE   (United States)

Author keywords

Alzheimer's disease; Dementia with Lewy bodies; Magnetic resonance spectroscopy

Indexed keywords

CHOLINE; CREATINE; INOSITOL; N ACETYLASPARTIC ACID; ASPARTIC ACID; N-ACETYLASPARTATE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; BRAIN SIZE; CELLULAR DISTRIBUTION; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CELL NECROSIS; NEUROIMAGING; OCCIPITAL LOBE; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ANALOGS AND DERIVATIVES; CINGULATE GYRUS; COMPARATIVE STUDY; LEWY BODY DISEASE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASPARTIC ACID; CREATINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; GYRUS CINGULI; HIPPOCAMPUS; HUMANS; LEWY BODY DISEASE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OCCIPITAL LOBE;

EID: 84903367735     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.01.001     Document Type: Article

References (50)

1. International Classification of Sleep Disorders-2: Diagnostic and Coding Manual 2005, AASM, American Academy of Sleep Medicine, Chicago.
2. Antuono P.G., Jones J.L., Wang Y., Li S.J. Decreased glutamate+ glutamine in Alzheimer's disease detected invivo with (1)H-MRS at 0.5 T. Neurology 2001, 56:737-742.
3. Bartha R., Smith M., Rupsingh R., Rylett J., Wells J.L., Borrie M.J. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:786-793.
4. Bitsch A., Bruhn H., Vougioukas V., Stringaris A., Lassmann H., Frahm J., Bruck W. Inflammatory CNS demyelination: histopathologic correlation with invivo quantitative proton MR spectroscopy. Am. J. Neuroradiol. 1999, 20:1619-1627.
5. Chao L.L., Schuff N., Kramer J.H., Du A.T., Capizzano A.A., O'Neill J., Wolkowitz O.M., Jagust W.J., Chui H.C., Miller B.L., Yaffe K., Weiner M.W. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology 2005, 64:282-289.
6. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain res. 2004, 1012:60-65. 10.1016/j.brainres.2004.02.079.
7. Ferguson K.J., MacLullich A.M.J., Marshall I., Deary I.J., Starr J.M., Seckl J.R., Wardlaw J.M. Magnetic resonance spectroscopy and cognitive function in healthy elderly men. Brain 2002, 125:2743-2749. 10.1093/Brain/Awf278.
8. Ferman T.J., Smith G.E., Boeve B.F., Ivnik R.J., Petersen R.C., Knopman D., Graff-Radford N., Parisi J., Dickson D.W. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004, 62:181-187.
9. Galasko D., Hansen L.A., Katzman R., Wiederholt W., Masliah E., Terry R., Hill L.R., Lessin P., Thal L.J. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch. Neurol. 1994, 51:888-895.
10. Glanville N.T., Byers D.M., Cook H.W., Spence M.W., Palmer F.B. Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochim. Biophys. Acta 1989, 1004:169-179.
11. Gomez-Isla T., Growdon W.B., McNamara M., Newell K., Gomez-Tortosa E., Hedley-Whyte E.T., Hyman B.T. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999, 53:2003-2009.
12. Graff-Radford J., Boeve B.F., Pedraza O., Ferman T.J., Przybelski S., Lesnick T.G., Vemuri P., Senjem M.L., Smith G.E., Knopman D.S., Lowe V., Jack C.R., Petersen R.C., Kantarci K. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 2012, 135:2470-2477.
13. Hamilton R.L. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000, 10:378-384.
14. Hattori N., Abe K., Sakoda S., Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 2002, 13:183-186.
15. Huang W., Alexander G.E., Chang L., Shetty H.U., Krasuski J.S., Rapoport S.I., Schapiro M.B. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology 2001, 57:626-632.
16. Jones R.S., Waldman A.D. 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. Neurol. Res. 2004, 26:488-495.
17. Kantarci K., Boeve B.F., Wszolek Z.K., Rademakers R., Whitwell J.L., Baker M.C., Senjem M.L., Samikoglu A.R., Knopman D.S., Petersen R.C., Jack C.R. MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology. Neurology 2010, 75:771-778.
18. Kantarci K., Ferman T.J., Boeve B.F., Weigand S.D., Przybelski S., Vemuri P., Murray M.M., Senjem M.L., Smith G.E., Knopman D.S., Petersen R.C., Jack C.R., Parisi J.E., Dickson D.W. Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology 2012, 79:553-560.
19. Kantarci K., Jack C.R., Xu Y.C., Campeau N.G., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Kokmen E., Tangalos E.G., Petersen R.C. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000, 55:210-217.
20. Kantarci K., Lowe V., Przybelski S.A., Senjem M.L., Weigand S.D., Ivnik R.J., Roberts R., Geda Y.E., Boeve B.F., Knopman D.S., Petersen R.C., Jack C.R. Magnetic resonance spectroscopy, beta-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology 2011, 77:951-958.
21. Kantarci K., Lowe V.J., Boeve B.F., Weigand S.D., Senjem M.L., Przybelski S.A., Dickson D.W., Parisi J.E., Knopman D.S., Smith G.E., Ferman T.J., Petersen R.C., Jack C.R. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol. Aging 2012, 33:2091-2105. 10.1016/j.neurobiolaging.2011.09.024.
22. Kantarci K., Petersen R.C., Boeve B.F., Knopman D.S., Tang-Wai D.F., O'Brien P.C., Weigand S.D., Edland S.D., Smith G.E., Ivnik R.J., Ferman T.J., Tangalos E.G., Jack C.R. 1H MR spectroscopy in common dementias. Neurology 2004, 63:1393-1398.
23. Kantarci K., Reynolds G., Petersen R.C., Boeve B.F., Knopman D.S., Edland S.D., Smith G.E., Ivnik R.J., Tangalos E.G., Jack C.R. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am. J. Neuroradiol 2003, 24:843-849.
24. Kantarci K., Weigand S.D., Przybelski S.A., Preboske G.M., Pankratz V.S., Vemuri P., Senjem M.L., Murphy M.C., Gunter J.L., Machulda M.M., Ivnik R.J., Roberts R.O., Boeve B.F., Rocca W.A., Knopman D.S., Petersen R.C., Jack C.R. MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology 2013, 81:126-133. 10.1212/WNL.0b013e31829a3329.
25. Kattapong V.J., Brooks W.M., Wesley M.H., Kodituwakku P.W., Rosenberg G.A. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch. Neurol. 1996, 53:678-680.
26. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J.Neural Transm. 2000, 107:1027-1063.
27. Lim S.M., Katsifis A., Villemagne V.L., Best R., Jones G., Saling M., Bradshaw J., Merory J., Woodward M., Hopwood M., Rowe C.C. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J.Nucl. Med. 2009, 50:1638-1645.
28. Lin A.P., Shic F., Enriquez C., Ross B.D. Reduced glutamate neurotransmission in patients with Alzheimer's disease - an invivo (13)C magnetic resonance spectroscopy study. Magma 2003, 16:29-42.
29. MacKay S., Ezekiel F., Di Sclafani V., Meyerhoff D.J., Gerson J., Norman D., Fein G., Weiner M.W. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 1996, 198:537-545.
30. McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
31. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
32. Miller B.L., Moats R.A., Shonk T., Ernst T., Woolley S., Ross B.D. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993, 187:433-437.
33. Molina J.A., Garcia-Segura J.M., Benito-Leon J., Gomez-Escalonilla C., del Ser T., Martinez V., Viano J. Proton magnetic resonance spectroscopy in dementia with Lewy bodies. Eur. Neurol. 2002, 48:158-163.
34. Murray M., Vemuri P., Ferman T., Dugger B., Jack C., Boeve B., Knopman D., Petersen R., Parisi J., Dickson D., Kantarci K. In dementia with Lewy bodies, rapid eye movement sleep behavior disorder is associated with reduced Alzheimer's disease pathology and hippocampal atrophy. Alzheimers Dement. 2012, 8. P13-PP4.
35. Murray M.E., Graff-Radford N.R., Ross O.A., Petersen R.C., Duara R., Dickson D.W. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011, 10:785-796. 10.1016/S1474-4422(11)70156-9.
36. Oz G., Nelson C.D., Koski D.M., Henry P.G., Marjanska M., Deelchand D.K., Shanley R., Eberly L.E., Orr H.T., Clark H.B. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J.Neurosci. 2010, 30:3831-3838.
37. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E.V., Lim K.O. Invivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn. Reson. Med. 1999, 41:276-284.
38. Roberts R.O., Geda Y.E., Knopman D.S., Cha R.H., Pankratz V.S., Boeve B.F., Ivnik R.J., Tangalos E.G., Petersen R.C., Rocca W.A. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008, 30:58-69.
39. Ross B.D., Bluml S., Cowan R., Danielsen E., Farrow N., Tan J. Invivo MR spectroscopy of human dementia. Neuroimaging Clin. N. Am. 1998, 8:809-822.
40. Rupsingh R., Borrie M., Smith M., Wells J.L., Bartha R. Reduced hippocampal glutamate in Alzheimer disease. Neurobiol. Aging 2011, 32:802-810. 10.1016/j.neurobiolaging.2009.05.002.
41. Saunders D.E., Howe F.A., van den Boogaart A., Griffiths J.R., Brown M.M. Aging of the adult human brain: invivo quantitation of metabolite content withproton magnetic resonance spectroscopy. J.Magn. Reson. Imaging 1999, 9:711-716.
42. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
43. Schuff N., Capizzano A.A., Du A.T., Amend D.L., O'Neill J., Norman D., Kramer J., Jagust W., Miller B., Wolkowitz O.M., Yaffe K., Weiner M.W. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 2002, 58:928-935.
44. Schuff N., Ezekiel F., Gamst A.C., Amend D.L., Capizzano A.A., Maudsley A.A., Weiner M.W. Region and tissue differences of metabolites in normally aged brain using multislice 1H magnetic resonance spectroscopic imaging. Magn. Reson. Med. 2001, 45:899-907.
45. Valenzuela M.J., Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001, 56:592-598.
46. Webb P.G., Sailasuta N., Kohler S.J., Raidy T., Moats R.A., Hurd R.E. Automated single-voxel proton MRS: technical development and multisite verification. Magn. Reson. Med. 1994, 31:365-373.
47. Wurtman R.J., Blusztajn J.K., Marie J.C. Autocannibalism of choline-containing membrane phospholipids in the pathogenesis of Alzheimer's disease. Neurochem. Int. 1985, 369-372.
48. Xuan X., Ding M., Gong X. Proton magnetic resonance spectroscopy detects a relative decrease of N-acetylaspartate in the hippocampus of patients with dementia with Lewy bodies. J.Neuroimaging Official J. Am. Soc. Neuroimaging 2008, 18:137-141. 10.1111/j.1552-6569.2007.00203.x.
49. Yoshita M., Taki J., Yamada M. Aclinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J.Neurol. Neurosurg. Psychiatry 2001, 71:583-588.
50. Zaccai J., McCracken C., Brayne C. Asystematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005, 34:561-566. 10.1093/ageing/afi190.